|
|
Post by CM kipper007 on Nov 12, 2015 22:28:50 GMT
|
|
|
|
Post by CM kipper007 on Nov 12, 2015 22:35:09 GMT
HA!
Robert Lanza, CSO of Massachusetts-based Ocata, agreed. “Regulatory roadblocks haven’t been much of a problem for us,” he told Drug Discovery & Development. “Now that we have over four years of safety data, regulatory agencies seem to be much more comfortable with the use of ES-derived cells.”
|
|
|
|
Post by harlem on Nov 12, 2015 22:56:00 GMT
This makes it worse imo mgt sold us out
|
|
|
|
Post by spambox on Nov 13, 2015 0:14:54 GMT
Indeed. Caught in their own web of lies and deceit.
|
|
sunny
Junior Member
Posts: 57 
|
Post by sunny on Nov 19, 2015 18:06:55 GMT
"Opportunities multiply as they are seized"
$85.00
|
|
|
|
Post by casualinvestor on Nov 19, 2015 18:54:52 GMT
HA! Robert Lanza, CSO of Massachusetts-based Ocata, agreed. “Regulatory roadblocks haven’t been much of a problem for us,” he told Drug Discovery & Development. “Now that we have over four years of safety data, regulatory agencies seem to be much more comfortable with the use of ES-derived cells.” Some would call the trial entry critera SNAFUs a regulatory roadblock. |
|
sunny
Junior Member
Posts: 57
|
Post by sunny on Nov 19, 2015 19:00:10 GMT
|
|
|
|
Post by spambox on Nov 19, 2015 20:48:30 GMT
HA! Robert Lanza, CSO of Massachusetts-based Ocata, agreed. “Regulatory roadblocks haven’t been much of a problem for us,” he told Drug Discovery & Development. “Now that we have over four years of safety data, regulatory agencies seem to be much more comfortable with the use of ES-derived cells.” Some would call the trial entry critera SNAFUs a regulatory roadblock. I'd call it an Ocata SNAFU. I bet Astellus were annoyed seeing this article published - increases the chances of a competitive bidder, one would think. |
|
